A Happy Pill for Some Biotechs
A Happy Pill for Some Biotechs Analysts predict 2003’s rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers.
A Happy Pill for Some Biotechs Analysts predict 2003’s rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers.
Biotech: A Coming Boom — or Bust? Two industry veterans lay out contrasting views about what the sector and its investors can expect over the next 12 months.
Biotech may be poised for “big year” Biotechnology is poised for a boom year in 2004, wrapping up 2003 with a strong recovery and plenty of reason for optimism, in the forecast of G. Steven Burrill, chief executive officer of the San Francisco-based life sciences merchant bank, Burrill & Co.
Biotech may be poised for “big year” Biotechnology is poised for a boom year in 2004, wrapping up 2003 with a strong recovery and plenty of reason for optimism, in the forecast of G. Steven Burrill, chief executive officer of the San Francisco-based life sciences merchant bank, Burrill & Co.
Got Life? Corporate lawyers haven’t had much to celebrate since the Internet bubble burst, but a recent stock market run on life sciences companies is breathing new buoyancy into some practices.
When Patents Persist What if that patent you’re paying royalties on suddenly gets extended? Have you negotiated the best licensing deal possible?
Amgen’s Cannibalistic Ways If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.
Amgen’s Cannibalistic Ways If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.
FDA Chief Eyes Path for Copycat Biotech Drugs Food and Drug Administration Commissioner Mark McClellan said on Friday it may be justifiable for regulators to approve generic forms of biotech drugs even if they have not been through the same lengthy clinical trials required of the original drugs.
Boston’s Biotech Moment The future is moving out of dusty library stacks and into pristine laboratories on both sides of the Charles River, making this area the national leader in biotechnology. The boom is driven by a new breed of intellectual wearing a white lab coat and using science to breach the barrier between academia […]